The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00720-0
A View Beyond HbA1c: Role of Continuous Glucose Monitoring
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0619-1
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0657-8
Lack of Treatment Persistence and Treatment Nonadherence as Barriers to Glycaemic Control in Patients with Type 2 Diabetes
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0590-x
The Potential Impact of the FreeStyle Libre Flash Glucose Monitoring System on Mental Well-Being and Treatment Satisfaction in Patients with Type 1 Diabetes: A Prospective Study
来源期刊:Diabetes TherapyDOI:10.1007/S13300-019-0616-4
Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00733-9
Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0669-4
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00728-6
Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0630-6
Insights for Care: The Healthcare Utilisation and Cost Impact of Managing Type 2 Diabetes-Associated Microvascular Complications
来源期刊:Diabetes TherapyDOI:10.1007/s13300-018-0548-4
Cardiovascular Risk in Type 1 Diabetes Mellitus
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0612-8
Thyroid Dysfunction and Type 2 Diabetes Mellitus: Screening Strategies and Implications for Management
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00700-4
Measurement Uncertainty Impacts Diagnosis of Diabetes Mellitus: Reliable Minimal Difference of Plasma Glucose Results
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00740-w
Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00698-9
A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor Use
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0611-9
Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0654-y
Association of the Serum Total Cholesterol to Triglyceride Ratio with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes: A Community-Based Study
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0579-5
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00723-x
A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019
来源期刊:Diabetes TherapyDOI:10.1007/s13300-018-0559-1
Rationale, Design, and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized, Parallel-Group Comparison Trial
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00717-9
Improving Type 2 Diabetes Management in General Practice Using a Second-Generation Basal Insulin Analogue Insulin Glargine 300 U/mL: A Practical Guide
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00704-0
Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00742-8
The Relationship Between Sleep and Quality of Life in Type 1 Diabetes Patients
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0621-7
Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00752-6
Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0606-6
European Association for the Study of Diabetes 2019 Conference: Podcast Overview of the Conference
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-00714-y
Efficacy Comparison of Preprandial and Postprandial Prandilin 25 Administration in Patients with Newly Diagnosed Type 2 Diabetes Using a Continuous Glucose Monitoring System
来源期刊:Diabetes TherapyDOI:10.1007/s13300-018-0545-7
Establishing Expert, Multi-Disciplinary, Peer-Reviewed Consensus to Lead a Paradigm Shift in Optimal Blood Glucose Management
来源期刊:Diabetes TherapyDOI:10.1007/s13300-019-0598-2